The median survival time for lung cancer patients with the MSH3 Ala1045Thr homozygous variant (GG) was higher than for those with the wild-type genotype (AA) (MST = 16.7 vs 8.7, 95% CI 0.32–1.05, Log-rank p = 0.14). Here, MSH3 is linked to lung carcinoma.